Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00OTL
|
|||
| Former ID |
DNCL001857
|
|||
| Drug Name |
Vernakalant
|
|||
| Synonyms |
Vernakalant; 794466-70-9; UNII-9G468C8B13; Vemakalant; RSD1235; 9G468C8B13; (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol; 3-Pyrrolidinol,1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-; RSD-1235; Vernakalant [INN:BAN]; SCHEMBL410062; CHEMBL2111112; DTXSID60229659; VBHQKCBVWWUUKN-KZNAEPCWSA-N; CHEBI:135956; EX-A2465; ZINC22010910; 4151AH; AKOS027326205; DB06217; SB16873; CS-0276; API0014187; RL05068; 3-Pyrrolidinol, 1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)-, (3R)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Atrial fibrillation [ICD-11: BC81.3; ICD-10: I48] | Phase 3 | [1] | |
| Company |
Cardiome Pharma; Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H31NO4
|
|||
| Canonical SMILES |
COC1=C(C=C(C=C1)CCOC2CCCCC2N3CCC(C3)O)OC
|
|||
| InChI |
1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1
|
|||
| InChIKey |
VBHQKCBVWWUUKN-KZNAEPCWSA-N
|
|||
| CAS Number |
CAS 794466-70-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:135956
|
|||
| ADReCS Drug ID | BADD_D02351 | |||
| SuperDrug ATC ID |
C01BG11
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.